(NASDAQ: ACRS) Aclaris Therapeutics's forecast annual revenue growth rate of -27.99% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 6.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.79%.
Aclaris Therapeutics's revenue in 2025 is $27,080,000.On average, 5 Wall Street analysts forecast ACRS's revenue for 2025 to be $728,881,332, with the lowest ACRS revenue forecast at $183,577,521, and the highest ACRS revenue forecast at $1,421,475,746. On average, 4 Wall Street analysts forecast ACRS's revenue for 2026 to be $617,306,201, with the lowest ACRS revenue forecast at $183,577,521, and the highest ACRS revenue forecast at $1,557,194,536.
In 2027, ACRS is forecast to generate $782,597,401 in revenue, with the lowest revenue forecast at $183,577,521 and the highest revenue forecast at $1,707,199,514.